Punjab Chemicals Business Update Q4FY23:
- The industry faced challenges in the last quarter, including inventory and price corrections, leading to a slowdown in demand for some products.
- Despite these challenges, the company performed well in certain product categories and has seen a pick-up in demand for some products in the current quarter.
Future Outlook:
- The management believes that the recent challenges are temporary and do not reflect the overall growth journey of the company.
- The company is recalibrating its growth strategy and improving processes to adapt to market dynamics.
- Efforts are being made to professionalize the management team, strengthen technical capabilities, enhance environmental health and safety (EHS) processes, and invest in asset reliability and renewal.
- The R&D team is being rebuilt and strengthened, with the development of new products and partnerships with universities for further research.
- The focus for the next year will be on signing formal contracts with multinational companies (MNCs) for product development and manufacturing, capitalizing on developed molecules, and continuing R&D initiatives.
- The company is exploring alternate sources of energy to reduce energy costs.
Tailwinds:
- Positive momentum and growth achieved in previous years.
- Strengthening of management and leadership team.
- Focus on R&D and development of new products.
- Potential contracts with MNCs.
- Increasing market share in the export market.
Reason for Current Performance:
The company acknowledged that the drop in performance was primarily due to lower domestic demand in the AgChem sector, which is the largest part of their portfolio. They also mentioned that there was a slowdown in the pharma sector and a drop in exports, particularly in Europe, due to inventory correction and price reductions.
The analysts questioned the explanation provided by the company, stating that the domestic AgChem business constitutes only about 12-13% of the total business and couldn’t account for the significant drop in overall performance. The company responded by emphasizing that Q4 was challenging due to inventory correction and unusual weather conditions throughout the year. They acknowledged that the slippage in Q4 numbers was higher than expected but expressed confidence in future growth prospects and reassured investors about long-term understanding with customers.
Regarding product approvals, the company shared updates on four products. They mentioned delays in launching a pharma intermediate product due to customer inventory correction and market turmoil. For two agro products, one herbicide already received EU approval and is expected to be registered in multiple European states by September, while another product is undergoing batch analysis and expected to be registered within the next six to eight months. The company clarified that the first two products, including a KSM and an AgChem for Brazil, have already been received and sales have commenced, with the sales reflecting post Q3.
In response to a question about Chinese manufacturers impacting pricing in the market, the company explained that China’s opening up after a prolonged period of closure has led to price reductions as they are desperate to sell their products at lower prices. However, they believed that this price reduction is a temporary phenomenon and expected prices to stabilize by Q2 for the European market and gradually recover in the Indian market from Q1 onwards.
Regarding future business, the company mentioned that it has been engaging in discussions with potential clients for specific products and molecules. These discussions have reached an advanced stage, with technology transfer documents and NDAs being exchanged, and some products already developed. In the coming months, the company expects these discussions to result in formal contracts, including multi-year contracts with take-or-pay clauses and clearly defined terms.
The company highlighted that these future contracts would involve multi-step processes, with most products requiring a minimum of five to seven steps. They also mentioned the possibility of backward integration within their factory or within India to secure the supply chain against market shocks. The company anticipates working with a product basket range of $50 to $300, which represents higher-value and more complex products compared to their current offerings.
In terms of market dynamics, the company discussed the entry of Chinese manufacturers and the impact on pricing. They noted that China, after being closed for two years, is now desperate to sell products at lower prices. However, they expressed confidence that the situation will stabilize by the second quarter for the European market and gradually in the first quarter for the Indian market.
The company emphasized that despite the challenges posed by the entry of Chinese manufacturers and inventory correction, they believe their competitive processes and efforts to develop local suppliers will help them maintain or increase their market share. They also highlighted their progress in Latin America, where they have gained market share against Chinese competitors.
Overall, the company remains optimistic about future growth and expects strong performance in the upcoming quarters, driven by the formalization of contracts, the development of new products, and their competitive position in the market.
| Subscribe To Our Free Newsletter |
